Online inquiry

IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ870MR)

This product GTTS-WQ870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7043MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ14945MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ1089MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ7622MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ7102MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ6476MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ3882MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ3310MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ASN-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW